Drug Profile
SCIO 323
Alternative Names: SCIO-323Latest Information Update: 26 May 2010
Price :
$50
*
At a glance
- Originator Scios
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 26 May 2010 Discontinued - Phase-I for Rheumatoid arthritis in USA (PO)
- 05 May 2003 Scios has been acquired by Johnson & Johnson
- 10 Feb 2003 SCIO 323 is available for licensing (http://www.sciosinc.com)